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Introduction
The incidence of breast cancer has been increasing
steadily over the past 60 years [1], today affecting one in
eight women in the United States [2]. Despite tremendous
efforts to understand the disease, less than 50% of all
cases are of known etiology such as genetic inheritance,
first-degree relatives with breast cancer, and age of men-
struation and menopause [3].
A large group of lipophilic organochlorines are found to
persist in the environment and to biomagnify through the
food chain. This group includes pesticides, polychlorinated
biphenyls (PCBs) and polychlorinated dibenzo-dioxins/
polychlorinated dibenzo-furans [4–8]. Many of these
compounds can interfere with a wide range of hormonal
responses [9–13], including estrogen receptor (ER)-
mediated responses. Due to their lipophilic nature,
bp = base pair; DMEM = Dulbecco’s modified Eagle’s medium; E2 = 17β-estradiol; ER = estrogen receptor; PCB = polychlorinated biphenyl; PCR =
polymerase chain reaction; POC = persistent organochlorine; TCDD = 2,3,7,8 tetrachlorodibenzo-p-dioxin.
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Abstract
Background: Environmental persistent organochlorines (POCs) biomagnify in the food chain, and the
chemicals are suspected of being involved in a broad range of human malignancies. It is speculated
that some POCs that can interfere with estrogen receptor-mediated responses are involved in the
initiation and progression of human breast cancer. The tumor suppressor gene BRCA1 plays a role in
cell-cycle control, in DNA repair, and in genomic stability, and it is often downregulated in sporadic
mammary cancers. The aim of the present study was to elucidate whether POCs have the potential to
alter the expression of BRCA1.
Methods: Using human breast cancer cell lines MCF-7 and MDA-MB-231, the effect on BRCA1
expression of chemicals belonging to different classes of organochlorine chemicals (the pesticide
toxaphene, 2,3,7,8-tetrachlorodibenzo-p-dioxin, and three polychlorinated biphenyls [PCB#138,
PCB#153 and PCB#180]) was measured by a reporter gene construct carrying 267 bp of the BRCA1
promoter. A twofold concentration range was analyzed in MCF-7, and the results were supported by
northern blot analysis of BRCA1 mRNA using the highest concentrations of the chemicals.
Results: All three polychlorinated biphenyls and 2,3,7,8-tetrachlorodibenzo-p-dioxin reduced 17β-
estradiol (E2)-induced expression as well as basal reporter gene expression in both cell lines, whereas
northern blot analysis only revealed a downregulation of E2-induced BRCA1 mRNA expression in
MCF-7 cells. Toxaphene, like E2, induced BRCA1 expression in MCF-7.
Conclusion: The present study shows that some POCs have the capability to alter the expression of
the tumor suppressor gene BRCA1 without affecting the cell-cycle control protein p21Waf/Cip1. Some
POCs therefore have the potential to affect breast cancer risk.
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organochlorines accumulate in the adipose tissue, can
cross the placenta and are found in the breast milk [14].
The chemicals give rise to life-long exposure and are sup-
posed to disturb early development. There is, however, a
great epidemiological disparity in the literature regarding
whether an association exists between POCs and breast
cancer [15,16].
The breast cancer susceptibility gene, BRCA1 [17], is
linked to familial breast cancer [18], and it is found to be
downregulated in sporadic breast and ovarian cancers
[19,20]. Decreased expression of BRCA1 promotes cell
proliferation and can cause cell transformation [20,21].
The function of BRCA1 remains unknown, but strong evi-
dence suggests a role in cell-cycle control and DNA repair
[22,23]. Furthermore, BRCA1 expression is regulated by
17β-estradiol (E2) [24,25].
To address whether POCs could affect BRCA1 expres-
sion, we studied the effect on BRCA1 promoter activity
using a transient reporter gene assay and the effect on
the BRCA1 mRNA level by northern blot analysis in two
human breast cancer cell lines. Furthermore, the effect on
the estrogen-responsive gene (pS2) was studied, as well
the effect on the cell-cycle regulator (p21Waf/Cip1), in
order to shed some light on the mechanistic pathways
involved.
Materials and methods
Chemicals
Toxaphene (technical mixture; Dr Ehrenstorfer, Augsberg,
Germany), 2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD)
(Wellington Laboratories Inc., Guelph, Ontario, Canada),
PCB#138, PCB#153 and PCB#180 (Dr Ehrenstorfer),
E2 (Sigma-Aldrich Denmark A/S, Copenhagen, Denmark),
and ICI 182780 (AstraZeneca, Luton, UK) were used. All
compounds were dissolved in ethanol except TCDD,
which was dissolved in dimethyl sulfoxide. All concentra-
tions used were nontoxic as revealed by the Cytotoxicity
Assay (Promega Corporation, Madison, Wisconsin, USA)
and by measurement of total protein (BCA protein
reagent; Perbio Science, Helsinborg, Sweden).
Plasmids
The plasmid pGL12 contains 267 bp, spanning –224 to
+43 bp of the BRCA1 promoter-α, subcloned upstream
of the luciferase gene [26]. The plasmid pHEO1 contains
full-length human ERα cDNA [27]. The plasmid pON249
encodes  β-galactosidase under control of a CMV pro-
moter [28], and was used as the internal standard for
transfection efficiencies.
Reporter gene assay
MCF-7(BUS) cells (ER responsive) and MDA-MB-231
cells (ER nonresponsive) were cultured as described
elsewhere [9,29]. For experiments, 7.3 × 105 MCF-
7(BUS) cells or 5 × 105 MDA-MB-231 cells were seeded
in six-well trays in DMEM (without phenol red) media con-
taining charcoal-depleted fetal bovine serum (Hyclone
Europe, Perbio Science, Erembodegem-Aalst, Belgium).
MCF-7(BUS) cells were exposed to the given chemicals
and transfected with 1.4 µg pGL12 and 0.4 µg pON249
using 5 µl fugene (Roche, Mannheim, Germany). Cells
were harvested in lysis buffer (Roche) 24 hours after
exposure and transfection. Luciferase activity was mea-
sured using lysis buffer containing 0.5 mM luciferin
(Amersham Pharmacia Biotech, Uppsala, Sweden) and
0.5 mM ATP (Sigma). The β-galactosidase activity was
measured by a chemiluminescence kit (Roche). MDA-
MB-231 cells were exposed and harvested as MCF-
7(BUS) but were transfected with 1.5 µg pGL12 using
6 µl fugene for 48 hours. Cotransfection with ER was
carried out with 0.5 µg pHEO1.
Total RNA isolation
On day 1, 2.2 × 106 cells were seeded in 75 cm2 culture
flasks and grown for 24 hours in fetal calf serum contain-
ing media. The cells were starved in serum-free media on
day 2 to obtain G1-synchronization, and they were
exposed to chemicals in charcoal-depleted fetal bovine
serum media on day 3. Total RNA was harvested after
22 hours of chemical exposure (PUREScript; Gentra
Systems, Minneapolis, Minnesota, USA).
Northern blot and hybridization
A BRCA1 probe was produced by PCR on genomic DNA
against exon 11 (5′-GAGAGGCATCCAGAAAAGTATC-
AGG-3′ and 5′-CTCTGGGAAAGTATCGCTGTCATG-3′)
of the BRCA1 gene (882–2216 bp of BRCA1 cDNA
[17]). Twenty micrograms of total RNA was used for
northern blot analysis (Zeta-probe membrane; Bio-Rad,
Hercules, California, USA). The 32P-labeled BRCA1 probe
was made by random primed labeling (Megaprime; Amer-
sham Pharmacia Biotech), and was hybridized overnight at
42°C in 50% formamide (as described by the manufac-
turer). The pS2-specific probe and the internal control (the
GADPH probe) were used as described elsewhere
[13,29]. The blots were visualized by a PhosphorImager
and quantified with ImageQuant (Molecular Dynamics
Amersham Biosciences, Sunnyvale, California, USA).
p21Waf/Cip1 protein level
The p21Waf/Cip1 protein was quantified on 24 hour expo-
sure of MCF-7(BUS) to the given chemicals using the
Waf1 Elisa kit (Oncogene Research Products, San Diego,
California, USA).
Statistics
Statistical analysis was carried out in the Microsoft Excel
standard diagram for independent samples test. P values
were calculated using the two-tailed t-test two sample,
assuming unequal variances.Page 3 of 7
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Results
Reporter gene assay
The dose–response effects of the chemicals on the
BRCA1 promoter–luciferase construct (pGL12) in MCF-
7(BUS) are presented in Table 1. In MCF-7(BUS), TCDD,
ICI 182780, and the PCBs all significantly reduced the
basal (ethanol) and the E2-induced promoter activity at
the maximum concentrations tested (TCDD, 100 nM; ICI
182780 and PCBs, 10 µM). However, 10 µM toxaphene
significantly induced basal promoter activity. TCDD and
the pure ER antagonist ICI 182780 had the potential to
decrease basal and E2-induced promoter activity at 100
and 10 pM, respectively, while PCB#138 had the poten-
tial to decrease E2-induced promoter activity at 100 pM.
All chemicals (TCDD, 10 nM; ICI 182780 and PCBs,
10 µM) significantly reduced the BRCA1-promoter activity
in MDA-MB-231. Cotransfection of the ER into MDA-MB-
231 showed that the BRCA1 promoter is indeed induced
by E2 (Table 1); however, only twofold induction occurred
compared with the fivefold induction in MCF-7(BUS).
Northern blot analysis
To assess whether the findings in the reporter gene assay
are also valid for genomic BRCA1 mRNA expression,
northern blot analysis was carried out to measure the
effect on the BRCA1 mRNA level with each compound at
10 µM, except for TCDD at 10 nM and ICI 182780 at
100 nM. Figure 1 shows a PhosphorImager image of
BRCA1, pS2 and GADPH hybridizations to a northern
blot. The analyzed data for BRCA1  are presented in
Fig. 2. E2 induced BRCA1 mRNA expression twofold,
and all compounds except toxaphene significantly
decreased the E2-induced BRCA1 expression in MCF-7.
Toxaphene increased the basal BRCA1 mRNA expres-
sion, while ICI 182780 downregulated basal and E2-
induced expression. No effect of the chemicals on
BRCA1 mRNA expression was measured in the ER non-
responsive MDA-MB-231 cells.
To further address whether ER mediates the observed
deregulation of BRCA1 mRNA, expression of the ER
responsive gene pS2 was measured in parallel (Fig. 3a). A
2.5-fold induction of pS2 by E2 was observed, and a
twofold induction by toxaphene confirmed its ER agonistic
behavior. ICI 182780 significantly decreased basal and
E2-induced pS2 expression, whereas TCDD significantly
reduced E2-induced pS2 mRNA expression. The three
PCBs did not significantly affect the pS2 expression.
p21Waf/Cip1 study
To address whether the observed response could be a
direct consequence of changes in cell-cycle regulation,
we determined the effect of the POCs on the negative
cell-cycle regulator p21Waf/Cip1. As shown in Fig. 3b, the
POCs generally did not affect the p21Waf/Cip1 protein level.
Toxaphene, however, decreased the basal p21Waf/Cip1
level like E2. Similar to ICI 182780, TCDD elicited an anti-
estrogenic effect on cotreatment with E2.
Discussion
BRCA1 mRNA expression is frequently downregulated in
sporadic breast and ovarian cancers [19,20]. This altered
regulation is generally not correlated with mutations within
the gene [30]. The present study demonstrated that
POCs  in vitro had the potential to deregulate BRCA1
promoter activity and mRNA expression in human breast
cancer cell lines. Using an E2-responsive construct carry-
ing the key positive regulatory element of the BRCA1
promoter upstream of the luciferase gene [26,31], we
found that TCDD, PCB#138, PCB#153, and PCB#180
can downregulate the basal as well as the E2-induced
BRCA1 promoter activity in both the ER-positive cell line
(MCF-7(BUS)) and in the ER-negative cell line (MDA-MB-
231). However, toxaphene induced basal promoter activity
(Table 1).
The inhibiting effect of TCDD and the three PCBs were
confirmed by northern blot analysis on the E2-induced
BRCA1 mRNA level in MCF-7 (Fig. 2). E2 induced the
BRCA1 mRNA level twofold, and the observed estrogen-
like activity of toxaphene supports earlier findings [32,33].
At concentrations of 10 µM, the three PCBs had the
capacity to downregulate both basal and E2-induced
BRCA1 promoter activity, while they only decreased the
E2-induced BRCA1 mRNA level. Furthermore, the PCBs
antagonized E2-induced pS2 mRNA expression, but it
was not statistically significant (Fig. 3a). The anti-
estrogenic potential of the three PCBs mediated via the
ER, causing an antiproliferative effect in MCF-7, has previ-
ously been published by our laboratory [9].
Jeffy  et al. found BRCA1 to be downregulated by
benzo[a]pyrene in an ER-dependent fashion, probably
through an aryl hydrocarbon receptor-mediated pathway
[34]. Using RT-PCR, however, Jeffy et al. did not observe
TCDD to downregulate BRCA1 in MCF-7. In the present
study, TCDD significantly reduced both BRCA1 promoter
activity as well as E2-induced BRCA1 (Fig. 2) and pS2
mRNA expression in MCF-7 (Fig. 3a; see [13]).
All the POCs except toxaphene significantly decreased
E2-induced  BRCA1 mRNA expression in MCF-7. No
effect was measured on the mRNA level in MDA-MB-231
(Fig. 2), which indicates the mechanism of action to be via
the ER. In MDA-MB-231, however, the POCs also
decreased the BRCA1 promoter activity, suggesting that
other pathways than the ER-mediated pathway should be
considered. We have shown that the three PCBs in MCF-
7(BUS) are antiproliferative and anti-estrogenic at 10 µM
[9], as has also been reported for TCDD [34], whereas
toxaphene has been shown to increase MCF-7 prolifera-
tion [33,35]. In the present study, the negative cell-cycle
Available online http://breast-cancer-research.com/content/4/6/R12regulator p21Waf/Cip1 was not affected by the PCBs, while
the effect of E2 was as expected [36] and toxaphene
decreased the p21Waf/Cip1 protein level. ICI 182780 and
TCDD increased the E2 reduced level to its normal level
(Fig. 3b). This suggests that the deregulation of BRCA1
observed in this study is not a simple consequence of
altered cell-cycle regulation. Since the reporter gene assay
also showed an effect of the POCs in MDA-MB-231,
further research is needed to elucidate the pathways of
the  BRCA1 deregulation as well as the involvement of
other regulatory sites outside of the 267 bp key regulatory
element of the BRCA1 promoter cloned in the pGL-12
vector. In addition, a possible effect on BRCA1 expres-
sion of the chemicals in combination and in a mimic of the
concentrations found in the adipose tissue should be
addressed.
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Table 1
Effect of persistent organochlorines on transient BRCA1–luciferase (pGL12) reporter gene expression in MCF-7(BUS) and
MDA-MB-231
Tox.Tech. +  ICI 182780 +  TCDD + 
MCF-7(BUS) Tox.Tech. 100 pM E2 ICI 182780 100 pM E2 TCDD 100 pM E2
Control 18 ± 2.9 100 ± 11.8 18 ± 0.3 100 ± 6.3 18 ± 0.8 100 ± 8.4
10 µM 36 ± 8.3* 59 ± 8.6* 5 ± 1.1* 8 ± 3.4* n.d. n.d.
1 µM 20 ± 2.5 96 ± 25.2 7 ± 0.5* 7 ± 0.6* n.d. n.d.
100 nM 20 ± 6.8 102 ± 16.8 5 ± 0.4* 5 ± 1.7* 7 ± 0.9* 46 ± 4.6*
10 nM 24 ± 8.1 95 ± 7.4 5 ± 0.7* 8 ± 2.4* 7 ± 0.8* 33 ± 2.6*
1 nM 23 ± 8.1 88 ± 21.8 5 ± 0.7* 46 ± 10.8* 8 ± 1.3* 39 ± 3.5*
100 pM 24 ± 9.3 108 ± 11.4 9 ± 0.3* 81 ± 5.0* 14 ± 2.5* 66 ± 12.6*
10 pM 17 ± 1.7 112 ± 4.2 12 ± 0.8* 109 ± 25.1 16 ± 4.0 110 ± 24.1
1 pM 21 ± 3.4 92 ± 18.9 15 ± 2.3 101 ± 55.8 25 ± 6.7 107 ± 13.8
PCB#138 +  PCB#153 +  PCB#180 + 
MCF-7(BUS) PCB#138 100 pM E2 PCB#153 100 pM E2 PCB#180 100 pM E2
Control 18 ± 3.0 100 ± 7.8 18 ± 2.1 100 ± 6.9 18 ± 1.7 100 ± 12.7
10 µM 7 ± 1.2* 59 ± 14.9* 8 ± 0.7* 75 ± 9.0* 9 ± 3.5* 70 ± 11.5*
1 µM 17 ± 1.5 81 ± 19.5 16 ± 3.5 92 ± 17.2 13 ± 4.0 105 ± 11.7
100 nM 16 ± 1.7 90 ± 4.9* 21 ± 0.9 97 ± 12.9 16 ± 1.4 110 ± 24.7
10 nM 17 ± 3.9 82 ± 10.5* 22 ± 4.4 113 ± 10.6 19 ± 5.4 107 ± 28.9
1 nM 19 ± 3.0 87 ± 4.0* 20 ± 5.1 131 ± 28.9 23 ± 7.9 94 ± 10.2
100 pM 18 ± 4.1 88 ± 6.5* 21 ± 6.4 95 ± 16.5 17 ± 6.4 108 ± 31.1
10 pM 19 ± 2.2 85 ± 21.2 22 ± 0.9 112 ± 26.7 21 ± 7.4 112 ± 11.3
1 pM 24 ± 5.3 86 ± 20.3 19 ± 6.2 111 ± 9.5 16 ± 5.0 109 ± 21.2
Tox.Tech. TCDD  PCB#138  PCB#153  PCB#180 
MDA-MB-231 Control (10 µM) (10 nM) (10 µM) (10 µM) (10 µM)
pGL12 93 ± 19.3 21 ± 8.1* 65 ± 11.5* 35 ± 1.3* 50 ± 10.6* 49 ± 7.0*
pGL12 +  100 ± 15.0 21 ± 6.6* 69 ± 8.6* 32 ± 6.9* 53 ± 6.0* 44 ± 5.6*
10 nM E2
pGL12/ER 57 ± 10.4 35 ± 11.6* 55 ± 15.5 45 ± 10.6 46 ± 12.8 48 ± 13.5
pGL12/ER +  100 ± 13.8 37 ± 21.3* 74 ± 35.8 65 ± 23.9* 60 ± 24.5* 58 ± 36.5
10 nM E2
All values are corrected with β-galactosidase values (MCF-7(BUS)) or protein (MDA-MB-231) and then normalized to 17β-estradiol (E2)-induced
cells (set to 100). The data are mean ± standard deviations of at least five or six measurements from two independent experiments. pGL12/ER,
cotransfection with the pHEO1-expressing estrogen receptor alpha; Tox.Tech., toxaphene (technical mixture); TCDD, 2,3,7,8 tetrachlorodibenzo-p-
dioxin; PCB, polychlorinated biphenyl. * P < 0.05 relative to the given control (ethanol/DMSO or E2).Available online http://breast-cancer-research.com/content/4/6/R12
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Figure 1
PhosphorImager images of hybridizations with BRCA1 (7.8 kb), pS2 (500 bp), and GADPH (1.3 kb) probes against the same northern blot
membrane with 20 µg/lane total RNA from MCF-7. Concentrations of the chemicals are as shown in Fig. 2. The filter represents only one
experiment. The collective data are presented in Figs 2 and 3. After hybridization with BRCA1, the filter was stripped and rehybridized with pS2
and then with GADPH. MDA-MB-231 data are not shown. E2, 17β-estradiol; Tox.Tech., toxaphene (technical mixture); Ici, ICI 182780; 
TCDD, 2,3,7,8 tetrachlorodibenzo-p-dioxin; PCB, polychlorinated biphenyl; EtOH, ethanol; DMSO, dimethyl sulfoxide.
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Figure 2
Effect of persistent organochlorines on BRCA1 mRNA expression in (a) MCF-7 and (b) MDA-MB-231. All values are normalized to the internal
control (GADPH) and then related to the solvent control (set to 1). Dark bars indicate cotreatment of 17β-estradiol and the given compound.
* P < 0.05 compared with solvent-treated cells, ** P < 0.05 compared with 17β-estradiol (10 nM)-exposed cells. Data are presented as
mean ± standard deviation of at least three independent experiments. E2, 17β-estradiol; Tox.Tech., toxaphene (technical mixture); 
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Solvent, EtOH or DMSO (a) (b)Conclusion
It was found that TCDD, PCB#138, PCB#153, and
PCB#180 decreased E2-induced BRCA1 promoter
activity and mRNA expression in human breast cancer cell
lines. Toxaphene induced the basal BRCA1 expression,
probably via inducing cell proliferation since it was found to
downregulate the cell-cycle protein p21Waf/Cip1. The pre-
sented data show that the ER is likely to play an essential
role in the deregulation of BRCA1, but the data indicate a
possible involvement of other pathways as well. The effect
of these POCs on BRCA1 expression may, however, for a
large part be a consequence of their anti-estrogenic, and
hence antiproliferative, effect. By deregulating BRCA1,
therefore, as has been found in sporadic breast cancers,
the POCs could impair the DNA repair machinery, the cell-
cycle control and the stress-induced apoptosis [37]. POCs
consequently could affect the overall risk of breast cancer.
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